Unprecedented access to novel CRISPR nucleases
Inscripta is a gene editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity. This includes developing a family of CRISPR enzymes (called MADzymes), bespoke nucleases for researchers and commercial partners, and a full suite of gene editing tools (software, instruments, and reagents) that will significantly increase the speed and efficiency of precision gene editing.
Boulder, CO – April 30, 2019 – Inscripta, developer of the first scalable platform for benchtop Digital Genome Engineering, today announced the appointment of Ron McGrath as Chief Financial Officer. Mr. McGrath has held leadership and financial roles for more than 25...